Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (not Assembly Biosciences, Inc.) on June 5, 2013, regarding events occurring on June 4, 2013. The filing details the results of the company's 2013 annual meeting of stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The primary material event reported is the election of five directors to the Board of Directors for a term expiring in 2014. The voting results were as follows:
- Anthony Altig: 10,154,480 For; 82,640 Against/Withheld; 6,062,813 Broker Non-Votes.
- Mark Auerbach: 10,171,618 For; 65,502 Against/Withheld; 6,062,813 Broker Non-Votes.
- Russell H. Ellison: 10,150,280 For; 86,840 Against/Withheld; 6,062,813 Broker Non-Votes.
- Joseph Felder: 10,135,229 For; 101,891 Against/Withheld; 6,062,813 Broker Non-Votes.
- Myron Z. Holubiak: 10,103,322 For; 133,798 Against/Withheld; 6,062,813 Broker Non-Votes.
Additionally, stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2013. The vote was 16,263,534 For, 11,911 Against, and 24,488 Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting outcomes.
Investor Verification Checklist
- Verify the correct registrant name is Ventrus Biosciences, Inc., as the input metadata referenced Assembly Biosciences, Inc.
- Confirm the tenure of the newly elected directors (expiring at the 2014 annual meeting).
- Note the significant number of broker non-votes (over 6 million) for the director elections.
- Review the 2013 Annual Report (10-K) for the financial data omitted in this 8-K filing.